demonstrated feasibility in a preclinical study by specifically inserting an anti‐CD19 CAR sequence into the programmed cell death protein 1 (PD1) gene based on the CRISPR/Cas9 systems by electrotransfection, thus inducing PD1 interference, and further enhancing the anti‐tumor activity.[26] This group further validated their excellent safety and efficacy in treating patients with r/r B cell non‐Hodgkin lymphoma (B‐NHL).[26]. Here, CD19 is linked to neoplasm.